Skip to main content

Allergan's Breast Implants Class Claims Dismissal Failed

Allergan's Breast Implants Class Claims Dismissal Failed

Allergan's Breast Implants Class Claims Dismissal Failed

Introduction

On March 19, U.S. District Judge Brian R. Martinotti, presiding over the federal Allergan Biocell breast implants litigation, ruled that Allergan, Inc. must face manufacturing defect, negligence per se, and other claims as they were not preempted.

According to a 121-page opinion, which was a response to the company's dismissal motion, Judge Martinotti tossed failure-to-warn claims and other allegations on preemption grounds but rejected the bid to knock out the class allegations over the Biocell textured breast implants.

The company had filed a supplemental brief on January 5 in the U.S. District Court for the District of New Jersey, asking the federal judge to dismiss claims against its breast implants on the grounds that the consolidated lawsuits are preempted by federal law.

The federal judge concluded that the claims asserted by the named plaintiffs and putative class members stem from the same course of conduct of Allergan, which shares an aligned interest in seeking damages from the company.

The company failed in its attempt to toss the manufacturing defect claims after the judge asserted that the claims are not preempted and should not be dismissed.

In July 2019, the United States Food and Drug Administration (FDA) had asked Allergan to recall its Biocell textured implants, which covered 246,831 implants in the U.S.

Currently, Allergan is facing hundreds of product liability lawsuits and class action lawsuits over its breast implants, each claiming that the textured design was unreasonably dangerous and defective, and the manufacturer knew that it increased the risk of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) yet failed to warn about those risks.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

Study Finds Toxic Metals in E-Cigs and U-Cigs Vapors

Categories: E-Cigarette: JUUL

As health concerns about e-cigarette use escalate, emerging research suggests that a newer class of vaping products—ultrasonic cigarettes or u-cigarettes—may pose even greater risks.

A study published in Environmental Health Perspectives in…

Appeals Court Upholds $611M Roundup Verdict

Categories: Roundup

A Missouri appeals court has upheld a massive Roundup verdict originally totaling $1.5 billion, but significantly reduced the final amount Bayer and its Monsanto unit must pay to $611 million.

The case involved three plaintiffs from New…

Valsartan “Wave 2” Bellwether Trial Schedule Set by Court

Categories: Valsartan

As the first Valsartan bellwether trial approaches in September 2025, the federal judge overseeing the multidistrict litigation (MDL) is preparing a second set of trials.

This move comes in anticipation of the possibility that parties may…

✍️ FREE—3000 Pages Medical Record Review Trial!                
No Contract. No Risk—Fully Customized, Free!

Only 10 Firms Accepted—Offer Ends June 30!